MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
0.7204
-0.0176
-2.38%
After Hours: 0.7305 +0.0101 +1.40% 19:32 03/06 EST
OPEN
0.7395
PREV CLOSE
0.7380
HIGH
0.7543
LOW
0.7150
VOLUME
166.25K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
0.6844
MARKET CAP
23.09M
P/E (TTM)
-0.5586
1D
5D
1M
3M
1Y
5Y
1D
Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy
Reuters · 2d ago
Skye Bioscience Inc. to Announce 2025 Financial Results and Business Update on Conference Call
Reuters · 2d ago
10 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at SKYE last week (0223-0227)?
Weekly Report · 5d ago
Weekly Report: what happened at SKYE last week (0216-0220)?
Weekly Report · 02/23 09:14
Skye Bioscience Publishes Corporate Presentation on Nimacimab–Semaglutide Obesity Combination Strategy
Reuters · 02/22 01:32
Skye Bioscience CFO Departs
Dow Jones · 02/20 23:00
Skye Bioscience CFO Kaitlyn Arsenault To Step Down, Effective Immediately; CEO Punit Dhillon Appointed Principal Accounting Officer
Benzinga · 02/20 21:15
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.